145% climb: Madrigal Pharmaceuticals' stock soars on positive study results

Madrigal Pharmaceuticals Inc.'s stock price more than doubled Thursday, closing up 145 percent at $265.61 per share, after the company announced results from mid-stage testing of its lead new drug candidate. The experimental therapy, MGL-3196, is a once-daily oral therapy being developed as a treatment for a severe form of a liver disease known as non-alcoholic steatohepatitis or NASH. NASH is considered a silent disease that has few or no symptoms. Its is characterized by the accumulation of…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news